Dengue virus seroprevalence among febrile patients in Bamako, Mali: Results of a 2006 surveillance study

Elena K. Phoutrides, Mamadou B. Coulibaly, Christine M. George, Adama Sacko, Sekou Traore, Kovi Bessoff, Michael R. Wiley, Korine N. Kolivras, Zach Adelman, Mohamed Traore, Elizabeth A. Hunsperger

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Dengue viruses (DENV) are endemic in over 100 countries worldwide, and annually 50 to 100 million people are infected by one of the four DENV serotypes, whereas over 2.5 billion people are at risk for infection. West African countries lack the surveillance to determine the true incidence of dengue; hence, this disease is likely significantly underestimated. In Mali, ∼14 million people are potentially at risk of acquiring a dengue infection. Methods and Findings: A serosurvey for DENV was conducted on 95 human serum samples obtained from the Institute National de Recherche en Sante Publique in 2006. DENV-specific IgM and IgG enzyme-linked immunosorbent assays were performed on all samples, and a subset was tested using the plaque-reduction neutralization test against the DENV and yellow fever virus (YFV). Samples collected during the acute infection (0-5 days postonset of symptoms) were tested for dengue NS1 antigen and reverse-transcriptase polymerase chain reaction for Flaviviruses, Alphaviruses, and Bunyaviruses RNA. A total of 87 (93%) of samples were positive for anti-DENV IgG antibodies. Of a subset of 13 IgG positive samples, 2 samples neutralized monotypically against DENV-1 and -2, whereas 3 others neutralized broadly against YFV and multiple DENV. Although no polymerase chain reaction positives were found, DENV NS1 was detected in 1 of the 20 acute samples tested. Conclusions: Of the 93 human serum samples tested, the dengue prevalence based on dengue IgG enzyme-linked immunosorbent assay results was 93%. Three DENV specific positive samples and two YFV positives were identified by plaque-reduction neutralization test. Finally, one sample tested positive for dengue NS1, thus suggestive of an acute infection within 14 days of obtaining the sample from the patient. Based on these serological data from this study, YFV and DENV appear to be co-circulating in Mali.

Original languageEnglish (US)
Pages (from-to)1479-1485
Number of pages7
JournalVector-Borne and Zoonotic Diseases
Volume11
Issue number11
DOIs
StatePublished - Nov 1 2011

Fingerprint

Mali
Dengue Virus
Seroepidemiologic Studies
Fever
Dengue
Yellow fever virus
Immunoglobulin G
Neutralization Tests
Infection
Orthobunyavirus
Enzyme-Linked Immunosorbent Assay
Alphavirus
Flavivirus
Reverse Transcriptase Polymerase Chain Reaction
Serum
Immunoglobulin M

Keywords

  • Dengue viruses
  • Flavivirus
  • Serosurvey
  • West Africa

ASJC Scopus subject areas

  • Microbiology
  • Infectious Diseases
  • Virology

Cite this

Phoutrides, E. K., Coulibaly, M. B., George, C. M., Sacko, A., Traore, S., Bessoff, K., ... Hunsperger, E. A. (2011). Dengue virus seroprevalence among febrile patients in Bamako, Mali: Results of a 2006 surveillance study. Vector-Borne and Zoonotic Diseases, 11(11), 1479-1485. https://doi.org/10.1089/vbz.2011.0622

Dengue virus seroprevalence among febrile patients in Bamako, Mali : Results of a 2006 surveillance study. / Phoutrides, Elena K.; Coulibaly, Mamadou B.; George, Christine M.; Sacko, Adama; Traore, Sekou; Bessoff, Kovi; Wiley, Michael R.; Kolivras, Korine N.; Adelman, Zach; Traore, Mohamed; Hunsperger, Elizabeth A.

In: Vector-Borne and Zoonotic Diseases, Vol. 11, No. 11, 01.11.2011, p. 1479-1485.

Research output: Contribution to journalArticle

Phoutrides, EK, Coulibaly, MB, George, CM, Sacko, A, Traore, S, Bessoff, K, Wiley, MR, Kolivras, KN, Adelman, Z, Traore, M & Hunsperger, EA 2011, 'Dengue virus seroprevalence among febrile patients in Bamako, Mali: Results of a 2006 surveillance study', Vector-Borne and Zoonotic Diseases, vol. 11, no. 11, pp. 1479-1485. https://doi.org/10.1089/vbz.2011.0622
Phoutrides, Elena K. ; Coulibaly, Mamadou B. ; George, Christine M. ; Sacko, Adama ; Traore, Sekou ; Bessoff, Kovi ; Wiley, Michael R. ; Kolivras, Korine N. ; Adelman, Zach ; Traore, Mohamed ; Hunsperger, Elizabeth A. / Dengue virus seroprevalence among febrile patients in Bamako, Mali : Results of a 2006 surveillance study. In: Vector-Borne and Zoonotic Diseases. 2011 ; Vol. 11, No. 11. pp. 1479-1485.
@article{175721fd176741db92f39994b59d0c1e,
title = "Dengue virus seroprevalence among febrile patients in Bamako, Mali: Results of a 2006 surveillance study",
abstract = "Background: Dengue viruses (DENV) are endemic in over 100 countries worldwide, and annually 50 to 100 million people are infected by one of the four DENV serotypes, whereas over 2.5 billion people are at risk for infection. West African countries lack the surveillance to determine the true incidence of dengue; hence, this disease is likely significantly underestimated. In Mali, ∼14 million people are potentially at risk of acquiring a dengue infection. Methods and Findings: A serosurvey for DENV was conducted on 95 human serum samples obtained from the Institute National de Recherche en Sante Publique in 2006. DENV-specific IgM and IgG enzyme-linked immunosorbent assays were performed on all samples, and a subset was tested using the plaque-reduction neutralization test against the DENV and yellow fever virus (YFV). Samples collected during the acute infection (0-5 days postonset of symptoms) were tested for dengue NS1 antigen and reverse-transcriptase polymerase chain reaction for Flaviviruses, Alphaviruses, and Bunyaviruses RNA. A total of 87 (93{\%}) of samples were positive for anti-DENV IgG antibodies. Of a subset of 13 IgG positive samples, 2 samples neutralized monotypically against DENV-1 and -2, whereas 3 others neutralized broadly against YFV and multiple DENV. Although no polymerase chain reaction positives were found, DENV NS1 was detected in 1 of the 20 acute samples tested. Conclusions: Of the 93 human serum samples tested, the dengue prevalence based on dengue IgG enzyme-linked immunosorbent assay results was 93{\%}. Three DENV specific positive samples and two YFV positives were identified by plaque-reduction neutralization test. Finally, one sample tested positive for dengue NS1, thus suggestive of an acute infection within 14 days of obtaining the sample from the patient. Based on these serological data from this study, YFV and DENV appear to be co-circulating in Mali.",
keywords = "Dengue viruses, Flavivirus, Serosurvey, West Africa",
author = "Phoutrides, {Elena K.} and Coulibaly, {Mamadou B.} and George, {Christine M.} and Adama Sacko and Sekou Traore and Kovi Bessoff and Wiley, {Michael R.} and Kolivras, {Korine N.} and Zach Adelman and Mohamed Traore and Hunsperger, {Elizabeth A.}",
year = "2011",
month = "11",
day = "1",
doi = "10.1089/vbz.2011.0622",
language = "English (US)",
volume = "11",
pages = "1479--1485",
journal = "Vector-Borne and Zoonotic Diseases",
issn = "1530-3667",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Dengue virus seroprevalence among febrile patients in Bamako, Mali

T2 - Results of a 2006 surveillance study

AU - Phoutrides, Elena K.

AU - Coulibaly, Mamadou B.

AU - George, Christine M.

AU - Sacko, Adama

AU - Traore, Sekou

AU - Bessoff, Kovi

AU - Wiley, Michael R.

AU - Kolivras, Korine N.

AU - Adelman, Zach

AU - Traore, Mohamed

AU - Hunsperger, Elizabeth A.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Background: Dengue viruses (DENV) are endemic in over 100 countries worldwide, and annually 50 to 100 million people are infected by one of the four DENV serotypes, whereas over 2.5 billion people are at risk for infection. West African countries lack the surveillance to determine the true incidence of dengue; hence, this disease is likely significantly underestimated. In Mali, ∼14 million people are potentially at risk of acquiring a dengue infection. Methods and Findings: A serosurvey for DENV was conducted on 95 human serum samples obtained from the Institute National de Recherche en Sante Publique in 2006. DENV-specific IgM and IgG enzyme-linked immunosorbent assays were performed on all samples, and a subset was tested using the plaque-reduction neutralization test against the DENV and yellow fever virus (YFV). Samples collected during the acute infection (0-5 days postonset of symptoms) were tested for dengue NS1 antigen and reverse-transcriptase polymerase chain reaction for Flaviviruses, Alphaviruses, and Bunyaviruses RNA. A total of 87 (93%) of samples were positive for anti-DENV IgG antibodies. Of a subset of 13 IgG positive samples, 2 samples neutralized monotypically against DENV-1 and -2, whereas 3 others neutralized broadly against YFV and multiple DENV. Although no polymerase chain reaction positives were found, DENV NS1 was detected in 1 of the 20 acute samples tested. Conclusions: Of the 93 human serum samples tested, the dengue prevalence based on dengue IgG enzyme-linked immunosorbent assay results was 93%. Three DENV specific positive samples and two YFV positives were identified by plaque-reduction neutralization test. Finally, one sample tested positive for dengue NS1, thus suggestive of an acute infection within 14 days of obtaining the sample from the patient. Based on these serological data from this study, YFV and DENV appear to be co-circulating in Mali.

AB - Background: Dengue viruses (DENV) are endemic in over 100 countries worldwide, and annually 50 to 100 million people are infected by one of the four DENV serotypes, whereas over 2.5 billion people are at risk for infection. West African countries lack the surveillance to determine the true incidence of dengue; hence, this disease is likely significantly underestimated. In Mali, ∼14 million people are potentially at risk of acquiring a dengue infection. Methods and Findings: A serosurvey for DENV was conducted on 95 human serum samples obtained from the Institute National de Recherche en Sante Publique in 2006. DENV-specific IgM and IgG enzyme-linked immunosorbent assays were performed on all samples, and a subset was tested using the plaque-reduction neutralization test against the DENV and yellow fever virus (YFV). Samples collected during the acute infection (0-5 days postonset of symptoms) were tested for dengue NS1 antigen and reverse-transcriptase polymerase chain reaction for Flaviviruses, Alphaviruses, and Bunyaviruses RNA. A total of 87 (93%) of samples were positive for anti-DENV IgG antibodies. Of a subset of 13 IgG positive samples, 2 samples neutralized monotypically against DENV-1 and -2, whereas 3 others neutralized broadly against YFV and multiple DENV. Although no polymerase chain reaction positives were found, DENV NS1 was detected in 1 of the 20 acute samples tested. Conclusions: Of the 93 human serum samples tested, the dengue prevalence based on dengue IgG enzyme-linked immunosorbent assay results was 93%. Three DENV specific positive samples and two YFV positives were identified by plaque-reduction neutralization test. Finally, one sample tested positive for dengue NS1, thus suggestive of an acute infection within 14 days of obtaining the sample from the patient. Based on these serological data from this study, YFV and DENV appear to be co-circulating in Mali.

KW - Dengue viruses

KW - Flavivirus

KW - Serosurvey

KW - West Africa

UR - http://www.scopus.com/inward/record.url?scp=81155153956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81155153956&partnerID=8YFLogxK

U2 - 10.1089/vbz.2011.0622

DO - 10.1089/vbz.2011.0622

M3 - Article

C2 - 21767159

AN - SCOPUS:81155153956

VL - 11

SP - 1479

EP - 1485

JO - Vector-Borne and Zoonotic Diseases

JF - Vector-Borne and Zoonotic Diseases

SN - 1530-3667

IS - 11

ER -